Does neuroimaging research examining the pathophysiology of posttraumatic stress disorder require medication-free patients?

Journal of Psychiatry and Neuroscience

Volumn 35, Issue 2, 2010, Pages 80-89

  Lanius, Ruth A ^a   Brewin, Chris R ^b   Bremner, J Douglas ^c   Daniels, Judith K ^a   Friedman, Matthew J ^d   Liberzon, Israel ^e   McFarlane, Alexander ^f   Schnurr, Paula P ^d   Shin, Lisa ^g   Stein, Murray ^h   Vermetten, Eric ⁱ  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g TUFTS UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CENTRAL MILITARY HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; KETAMINE; LAMOTRIGINE; LITHIUM CARBONATE; LORAZEPAM; METHAMPHETAMINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENYTOIN; PLACEBO; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRIAZOLAM; VENLAFAXINE;

AMYGDALOID NUCLEUS; BIPOLAR DISORDER; BRAIN BLOOD FLOW; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFECT; EMOTION; EPILEPSY; EPISODIC MEMORY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAJOR DEPRESSION; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TASK PERFORMANCE;

EID: 77649282212     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: 10.1503/jpn.090047     Document Type: Review

References (88)

1. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007;164:1476-88.
2. Francati V, Vermetten E, Bremner JD. Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings. Depress Anxiety 2007;24:202-18.
3. Damsa C, Kosel M, Moussally J. Current status of brain imaging in anxiety disorders. Curr Opin Psychiatry 2009;22:96-110.
4. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010;35:169-91.
5. Orr SP, Solomon Z, Peri T, et al. Physiologic responses to loud tones in Israeli veterans of the 1973 Yom Kippur War. Biol Psychiatry 1997; 41:319-26.
6. Orr SP, Metzger LJ, Lasko NB, et al. Physiologic responses to sudden, loud tones in monozygotic twins discordant for combat exposure: association with posttraumatic stress disorder. Arch Gen Psychiatry 2003;60:283-8.
7. Milad MR, Orr SP, Lasko NB, et al. Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res 2008;42:515-20.
8. Elman I, Ariely D, Mazar N, et al. Probing reward function in posttraumatic stress disorder with beautiful facial images. Psychiatry Res 2005;135:179-83.
9. Gilbertson MW, Paulus LA, Williston SK, et al. Neurocognitive function in monozygotic twins discordant for combat exposure: relationship to posttraumatic stress disorder. J Abnorm Psychol 2006; 115:484-95.
10. Vasterling JJ, Duke LM, Brailey K, et al. Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons. Neuropsychology 2002;16:5-14.
11. Golier JA, Yehuda R, Lupien SJ, et al. Memory performance in Holocaust survivors with posttraumatic stress disorder. Am J Psychiatry 2002;159:1682-8.
12. Nixon RD, Nishith P, Resick PA. The accumulative effect of trauma exposure on short-term and delayed verbal memory in a treatment-seeking sample of female rape victims. J Trauma Stress 2004;17:31-5.
13. Orr SP, Lasko NB, Metzger LJ, et al. Psychophysiologic assessment of women with posttraumatic stress disorder resulting from childhood sexual abuse. J Consult Clin Psychol 1998;66:906-13.
14. Vasterling JJ, Brailey K, Sutker PB. Olfactory identification in combat-related posttraumatic stress disorder. J Trauma Stress 2000;13:241-53.
15. Vasterling JJ, Rogers C, Kaplan E. Qualitative block design analysis in posttraumatic stress disorder. Assessment 2000;7:217-26.
16. Metzger LJ, Orr SP, Lasko NB, et al. Auditory event-related potentials to tone stimuli in combat-related posttraumatic stress disorder. Biol Psychiatry 1997;42:1006-15.
17. Mintzer MZ, Griffiths RR. Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes. Cogn Affect Behav Neurosci 2007;7:120-9.
18. Mirow S. Cognitive dysfunction associated with fluoxetine. Am J Psychiatry 1991;148:948-9.
19. Murphy SE, Downham C, Cowen PJ, et al. Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology (Berl) 2008;199:503-13.
20. Stein RA, Strickland TL. A review of the neuropsychological effects of commonly used prescription medications. Arch Clin Neuropsychol 1998;13:259-84.
21. Kilts C. In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2003;37 Suppl 1:19-28.
22. Shin LM, Rauch SL, Pitman RK. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci 2006;1071:67-79.
23. Frewen PA, Lanius RA. Toward a psychobiology of posttraumatic self-dysregulation: reexperiencing, hyperarousal, dissociation, and emotional numbing. Ann N Y Acad Sci 2006;1071:110-24.
24. Liberzon I, Sripada CS. The functional neuroanatomy of PTSD: a critical review. Prog Brain Res 2008;167:151-69.
25. Liberzon I, Martis B. Neuroimaging studies of emotional responses in PTSD. Ann N Y Acad Sci 2006;1071:87-109.
26. Loubinoux I, Boulanouar K, Ranjeva JP, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab 1999;19:1365-75.
27. Loubinoux I, Tombari D, Pariente J, et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 2005;27:299-313.
28. Peran P, Demonet JF, Cardebat D. Paroxetine-induced modulation of cortical activity supporting language representations of action. Psychopharmacology (Berl) 2008;195:487-96.
29. Del-Ben CM, Deakin JF, McKie S, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 2005;30:1724-34.
30. Murphy SE, Norbury R, O'Sullivan U, et al. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009;194:535-40.
31. Arce E, Simmons AN, Lovero KL, et al. Escitalopram effects on insula and amygdale BOLD activation during emotional processing. Psychopharmacology (Berl) 2008;196:661-72.
32. Harmer CJ, Mackay CE, Reid CB, et al. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006;59:816-20.
33. Morris JS, Frith CD, Perrett DI, et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 1996;383:812-5.
34. Peluso MA, Glahn DC, Matsuo K, et al. Amygdala hyperactivation in untreated depressed individuals. Psychiatry Res 2009;173:158-61.
35. Drevets WC. Neuroimaging abnormalities in the amygdala in mood disorders. Ann N Y Acad Sci 2003;985:420-44.
36. Mayberg HS. Defining the neural circuitry of depression: toward a new nosology with therapeutic implications. Biol Psychiatry 2007;61:729-30.
37. Norbury R, Mackay CE. Short-term antidepressant treatment and facial processing: Functional magnetic resonance imaging study. Br J Psychiatry 2007;190:531-2.
38. Mintzer MZ, Griffiths RR, Contoreggi C, et al. Effects of triazolam on brain activity during episodic memory encoding: a PET study. Neuropsychopharmacology 2001;25:744-56.
39. Mintzer MZ, Kuwabara H, Alexander M, et al. Dose effects of triazolam on brain activity during episodic memory encoding: a PET Study. Psychopharmacology (Berl) 2006;188:445-61.
40. Paulus MP, Feinstein JS, Castillo G, et al. Dose-dependent decrease of activation in bilateral amygdale and insula by lorazepam during emotion processing. Arch Gen Psychiatry 2005;62:282-8.
41. Kleinschmidt A, Bruhm H, Kruger G, et al. Effects of sedation, stimulation, and placebo on cerebral blood oxygenation: a magnetic resonance neuroimaging study of psychotropic drug action. NMR Biomed 1999;12:286-92.
42. Holcomb HH, Lahti AC, Medoff DR, et al. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001;25:165-72.
43. Abel KM, Allin MP, Kucharska-Pietura K, et al. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 2003;18:135-45.
44. Li X, Teneback CC, Nahas Z, et al. Interleaved transcranial magnetic stimulation/functional MRI confirms that lamotrigine inhibits cortical excitability in healthy young men. Neuropsychopharmacology 2004;29:1395-407.
45. Schlagenhauf F, Wüstenberg T, Schmack K, et al. Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur Neuropsychopharmacol 2008;18:589-99.
46. Higuchi Y, Sumiyoshi T, Kawasaki Y, et al. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr Res 2008;101:320-30.
47. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment. Arch Gen Psychiatry 2004;61:877-89.
48. Sheline YI, Barch DM, Donnelly JM, et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50: 651-8.
49. Walsh ND, Williams SC, Brammer MJ, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry 2007; 62:1236-43.
50. Smith GS, Reynolds CFR, Houck PR, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry Res 2009;171:1-9.
51. Caligiuri MP, Brown GG, Meloy MJ, et al. An fMRI study of affective state and medication on cortical and subcortical brain regions during motor performance in bipolar disorder. Psychiatry Res 2003; 123:171-82.
52. Blumberg HP, Donegan NH, Sanislow CA, et al. Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) 2005;183:308-13.
53. Keener MT, Phillips ML. Neuroimaging in bipolar disorder: a critical review of current findings. Curr Psychiatry Rep 2007;9:512-20.
54. Bremner JD, Innis RB, Ng CK, et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry 1997;54:246-54.
55. Seedat S, Warwick J, van Heerden B, et al. Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 2004;80:45-53.
56. Crespo-Facorro B, Roiz-Santiáñez R, Pérez-Iglesias R, et al. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1936-43.
57. Bremner JD, Mletzko T, Welter S, et al. Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. J Psychopharmacol 2005;19:159-65.
58. Mathew S, Price R, Shungu D, et al. A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder. J Psychopharmacol 2009 Feb. 9 [Epub ahead of print].
59. Vermetten E, Vythilingam M, Southwick SM, et al. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003;54:693-702.
60. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry 2008;69:959-65.
61. Diederich N J, Goetz CG. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 2008; 71:677-84.
62. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci 2009;1156:198-210.
63. Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with posttraumatic stress disorder. Psychiatr Serv 2003;54:1618-21.
64. Dewey M, Schink T, Dewey CF. Claustrophobia during magnetic resonance imaging: cohort study in over 55,000 patients. J Magn Reson Imaging 2007;26:1322-7.
65. Eshed I, Althoff CE, Hamm B, et al. Claustrophobia and premature termination of magnetic resonance imaging examinations. J Magn Reson Imaging 2007;26:401-4.
66. Grey SJ, Price G, Mathews A. Reduction of anxiety during MR imaging: a controlled trial. Magn Reson Imaging 2000;18:351-5.
67. Lanius RA, Tuhan I. Stage-oriented trauma treatment using dialectical behaviour therapy. Can J Psychiatry 2003;48:126-7.
68. Spinazzola J, Blaustein M, van der Kolk BA. Posttraumatic stress disorder treatment outcome research: The study of unrepresentative samples? J Trauma Stress 2005;18:425-36.
69. Rasetti R, Mattay VS, Wiedholz LM, et al. Evidence the altered amygdala activity in schizophrenia is related to clinical state and not genetic risk. Am J Psychiatry 2009;166:216-25.
70. Phillips ML, Travis MJ, Fagiolini A, et al. Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 2008;165:313-20.
71. Kaufman MJ, Henry ME, Frederick B, et al. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 2003;54:534-9.
72. Peres JF, Newberg AB, Mercante JP, et al. Cerebral blood flow changes during retrieval of traumatic memories before and after psychotherapy: a SPECT study. Psychol Med 2007;37:1481-91.
73. Pagani M, Hogberg G, Salmaso D, et al. Effects of EMDR psychotherapy on 99mTc-HMPAO distribution in occupation-related post-traumatic stress disorder. Nucl Med Commun 2007;28:757-65.
74. Felmingham K, Kemp A, Williams L, et al. Changes in anterior cingulate and amygdala after cognitive behavior therapy of posttraumatic stress disorder. Psychol Sci 2007;18:127-9.
75. Lindauer RJ, Booij J, Habraken JB, et al. Effects of psychotherapy on regional cerebral blood flow during trauma imagery in patients with post-traumatic stress disorder: a randomized clinical trial. Psychol Med 2008;38:543-54.
76. Goldapple K, Segal Z, Garson C, et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004;61:34-41.
77. Baxter LR Jr, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:681-9.
78. Prasko J, Horacek J, Zalesky R, et al. The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuroendocrinol Lett 2004;25:340-8.
79. Furmark T, Tillfors M, Marteinsdottir I, et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002;59:425-33.
80. Paquette V, Levesque J, Mensour B, et al. "Change the mind and you change the brain": effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 2003;18:401-9.
81. Straube T, Glauer M, Dilger S, et al. Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage 2006; 29:125-35.
82. Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007;164:778-88.
83. Whalley MG, Rugg MD, Smith APR, et al. Incidental retrieval of emotional contexts in PTSD and depression: an fMRI study. Brain Cogn 2009;69:98-107.
84. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51:189-92.
85. Brunet A, Orr SP, Tremblay J, et al. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent scriptdriven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008;42:503-6.
86. Stein MB, Kerridge C, Dimsdale JE, et al. Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007;20:923-32.
87. McGhee LL, Maani CV, Garza TH, et al. The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res 2009;30:92-7.
88. Moores KA, Clark CR, McFarlane AC, et al. Abnormal recruitment of working memory updating networks during maintenance of trauma-neutral information in post-traumatic stress disorder. Psychiatry Res 2008;163:156-70.